<DOC>
	<DOC>NCT00437606</DOC>
	<brief_summary>This study will investigate the effect of hepatic impairment on the pharmacokinetics, pharmacodynamics, safety and tolerability of GK Activator (2) in type 2 diabetes patients with mild and moderate hepatic impairment. Patients with type 2 diabetes, and with normal hepatic function, or mild or moderate hepatic impairment, will receive a single dose of GK Activator (2) 100mg po before breakfast, for assessment of pharmacokinetic, pharmacodynamic and safety parameters. The anticipated time on study treatment is &lt;3 months, and the target sample size is &lt;100 individuals.</brief_summary>
	<brief_title>A Study of the Pharmacokinetics/Pharmacodynamics of GK Activator (2) in Type 2 Diabetes Patients With Hepatic Impairment.</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<criteria>adult patients, 1875 years of age; type 2 diabetes; normal hepatic function, or mild or moderate hepatic impairment. type 1 diabetes, or latent autoimmune diabetes in adults; diabetic neuropathy, retinopathy or nephropathy; treatment with insulin or PPAR gamma agonist within 6 weeks of screening; clinically significant cardiovascular disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>